Immune Targeting in Blood Cancers

Dr Kyohei Nakamura

Team Head

The Immune Targeting in Blood Cancers Laboratory focuses on understanding the interplay between immunity and cancer cells in haematological malignancies such as multiple myeloma, B-cell lymphoma, and leukaemia.  Although immunotherapy has emerged as an important treatment option, these aggressive cancers are still difficult to cure.  Using preclinical models and clinical samples, the group aims to understand how cancer cells escape the immune system, and to develop new therapeutic approaches to prevent relapse. 


  • Uncovering the molecular mechanisms of immunosuppression in multiple myeloma and B-cell lymphoma
  • Harnessing immune-mediated control of minimal residual disease in blood cancers
  • Understanding the crosstalk between inflammation and immunity in the tumor microenvironment
  • Developing new immunotherapies against blood cancers


  • Mika Casey, Research Assistant
  • Basit Salik, PhD student
  • Cui Tu, student

Internal Collaborators

External Collaborators

  • Professor Peter Croucher, Garvan Institute, Sydney NSW
  • Dr Tri Phan, Garvan Institute, Sydney NSW
  • Professor Andrew Zannettino, University of Adelaide, Adelaide SA
  • Professor Maher Gandhi, Mater Research, Brisbane, QLD
  • Dr Ludovic Martinet, Toulouse Cancer Centre, Toulouse France
  • Dr Hervé Avet-Loiseau, Toulouse Cancer Centre, Toulouse France

We gratefully acknowledge the support of the following funding agencies

  • National Health and Medical Research Council
  • Leukaemia Foundation
  • Cure Cancer Australia and Cancer Australia